Erectile Dysfunction Therapeutic Pipeline Review H2 2015 Market Research Report at

Dallas, TX (PRWEB) January 26, 2015

The report “Erectile Dysfunction – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Erectile Dysfunction. Erectile dysfunction is the failure to get or keep an erection firm enough to have sexual intercourse. However, frequent Erectile dysfunction can be a sign of health problems that need treatment. Erectile dysfunction can have severe mental consequences as it can be joined to relationship difficulties and masculine self-image generally. Research indicates that approximately 40% of males suffer from erectile dysfunction. Complete report is available at .

It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. Companies discussed in this Erectile Dysfunction Pipeline Review H1 2015 report include Acorda Therapeutics, Inc., Apricus Biosciences, Inc., Aprogen, Inc., Bioheart, Inc., Biolab Sanus Farmaceutica Ltda., Corridor Pharmaceuticals Inc., Furiex Pharmaceuticals, Inc., Futura Medical plc, Hanmi Pharmaceuticals, Co. Ltd., IntelGenx Corp., Mezzion Pharma Co. Ltd., Mitsubishi Tanabe Pharma Corporation, NAL Pharmaceuticals Ltd., Pacific Therapeutics Ltd., Palatin Technologies, Inc., Pharmicell Co., Ltd., Sagene Pharmaceuticals, Inc., Suda Ltd, Yungjin Pharm Ind. Co., Ltd.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Order a Purchase copy of this report @ . (This is a premium report priced at US$ 2000 for a single user License.)

Table of Contents

List of Tables

Number of Products under Development for Erectile Dysfunction, H1 2015 10

Number of Products under Development for Erectile Dysfunction – Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Comparative Analysis by Unknown Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Investigation by Universities/Institutes, H1 2015 21

Erectile Dysfunction – Pipeline by Acorda Therapeutics, Inc., H1 2015 22

Erectile Dysfunction – Pipeline by Apricus Biosciences, Inc., H1 2015 23

Erectile Dysfunction – Pipeline by Aprogen, Inc., H1 2015 24

Erectile Dysfunction – Pipeline by Bioheart, Inc., H1 2015 25

Erectile Dysfunction – Pipeline by Biolab Sanus Farmaceutica Ltda., H1 2015 26

Erectile Dysfunction – Pipeline by Corridor Pharmaceuticals Inc., H1 2015 27

Erectile Dysfunction – Pipeline by Furiex Pharmaceuticals, Inc., H1 2015 28

Erectile Dysfunction – Pipeline by Futura Medical plc, H1 2015 29

Erectile Dysfunction – Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 30

Erectile Dysfunction – Pipeline by IntelGenx Corp., H1 2015 31

Erectile Dysfunction – Pipeline by Mezzion Pharma Co. Ltd., H1 2015 32

Erectile Dysfunction – Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 33

Erectile Dysfunction – Pipeline by NAL Pharmaceuticals Ltd., H1 2015 34

Erectile Dysfunction – Pipeline by Pacific Therapeutics Ltd., H1 2015 35

Erectile Dysfunction – Pipeline by Palatin Technologies, Inc., H1 2015 36

Erectile Dysfunction – Pipeline by Pharmicell Co., Ltd., H1 2015 37

Erectile Dysfunction – Pipeline by Sagene Pharmaceuticals, Inc., H1 2015 38

Erectile Dysfunction – Pipeline by Suda Ltd, H1 2015 39

Erectile Dysfunction – Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 40

Assessment by Monotherapy Products, H1 2015 41

Assessment by Combination Products, H1 2015 42

Number of Products by Stage and Target, H1 2015 44

Number of Products by Stage and Mechanism of Action, H1 2015 46

Number of Products by Stage and Route of Administration, H1 2015 48

Number of Products by Stage and Molecule Type, H1 2015 50

Erectile Dysfunction Therapeutics – Recent Pipeline Updates, H1 2015 83

Erectile Dysfunction – Dormant Projects, H1 2015 94

Erectile Dysfunction – Dormant Projects (Contd..1), H1 2015 95

Erectile Dysfunction – Dormant Projects (Contd..2), H1 2015 96

Erectile Dysfunction – Discontinued Products, H1 2015 97

Explore more reports on Men’s Health therapeutics industry at .

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Leave a Reply

Your email address will not be published. Required fields are marked *